SG11201907594TA - Methods of treating cancer with farnesyltransferase inhibitors - Google Patents

Methods of treating cancer with farnesyltransferase inhibitors

Info

Publication number
SG11201907594TA
SG11201907594TA SG11201907594TA SG11201907594TA SG11201907594TA SG 11201907594T A SG11201907594T A SG 11201907594TA SG 11201907594T A SG11201907594T A SG 11201907594TA SG 11201907594T A SG11201907594T A SG 11201907594TA SG 11201907594T A SG11201907594T A SG 11201907594TA
Authority
SG
Singapore
Prior art keywords
international
pct
methods
treating cancer
english
Prior art date
Application number
SG11201907594TA
Other languages
English (en)
Inventor
Antonio Gualberto
Catherine Scholz
Original Assignee
Kura Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/820,157 external-priority patent/US9956215B1/en
Application filed by Kura Oncology Inc filed Critical Kura Oncology Inc
Publication of SG11201907594TA publication Critical patent/SG11201907594TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201907594TA 2017-02-21 2018-02-21 Methods of treating cancer with farnesyltransferase inhibitors SG11201907594TA (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762461602P 2017-02-21 2017-02-21
US201762507749P 2017-05-17 2017-05-17
US201762519819P 2017-06-14 2017-06-14
US15/820,157 US9956215B1 (en) 2017-02-21 2017-11-21 Methods of treating cancer with farnesyltransferase inhibitors
US15/820,012 US10137121B2 (en) 2017-02-21 2017-11-21 Methods of treating cancer with farnesyltransferase inhibitors
US201762596653P 2017-12-08 2017-12-08
PCT/US2018/018989 WO2018156609A1 (en) 2017-02-21 2018-02-21 Methods of treating cancer with farnesyltransferase inhibitors

Publications (1)

Publication Number Publication Date
SG11201907594TA true SG11201907594TA (en) 2019-09-27

Family

ID=63253363

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907594TA SG11201907594TA (en) 2017-02-21 2018-02-21 Methods of treating cancer with farnesyltransferase inhibitors

Country Status (14)

Country Link
EP (3) EP3542800B1 (de)
JP (1) JP7289795B2 (de)
KR (3) KR20200090982A (de)
CN (4) CN109475550A (de)
AU (3) AU2018225566B2 (de)
BR (1) BR112019017375A2 (de)
CA (1) CA3053795A1 (de)
ES (2) ES2892157T3 (de)
IL (1) IL268722A (de)
MX (2) MX2019009821A (de)
PH (1) PH12019501918A1 (de)
SG (1) SG11201907594TA (de)
TW (3) TWI738314B (de)
WO (1) WO2018156609A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9956215B1 (en) 2017-02-21 2018-05-01 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020190604A1 (en) * 2019-03-15 2020-09-24 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5310652A (en) 1986-08-22 1994-05-10 Hoffman-La Roche Inc. Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5693517A (en) 1987-06-17 1997-12-02 Roche Molecular Systems, Inc. Reagents and methods for coupled high temperature reverse transcription and polymerase chain reactions
US5561058A (en) 1986-08-22 1996-10-01 Hoffmann-La Roche Inc. Methods for coupled high temperatures reverse transcription and polymerase chain reactions
CA1340843C (en) 1987-07-31 1999-12-07 J. Lawrence Burg Selective amplification of target polynucleotide sequences
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
ZA918965B (en) 1990-11-13 1992-08-26 Siska Diagnostics Inc Nucleic acid amplification by two-enzyme,self-sustained sequence replication
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP0631635B1 (de) 1992-03-04 2001-09-12 The Regents Of The University Of California Vergleichende genomhybridisierung
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5686472A (en) 1992-10-29 1997-11-11 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5491063A (en) 1994-09-01 1996-02-13 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
US5571673A (en) 1994-11-23 1996-11-05 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
EP0835101B1 (de) 1995-06-27 2004-06-09 Takeda Chemical Industries, Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
EP0946565B1 (de) 1996-12-20 2003-10-15 Tovarischestvo S Ogranichennoi Otvetstvennostju "Tabifarm" Verfahren und gerät zur herstellung von 1ss, 10ss-epoxy-13-dimethylamino-guaia-3(4)-en-6,12-olid-hydrochlorid
US6197350B1 (en) 1996-12-20 2001-03-06 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
HUP0100221A3 (en) 1998-01-16 2002-11-28 Takeda Pharmaceutical Sustained release compositions, process for producing the same and utilization thereof
WO1999045712A1 (en) 1998-03-05 1999-09-10 Formula One Administration Limited Data communication system
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
WO2000001691A1 (en) 1998-07-01 2000-01-13 Merck & Co., Inc. Process for making farnesyl-protein transferase inhibitors
ATE238811T1 (de) 1998-07-06 2003-05-15 Janssen Pharmaceutica Nv Inhibitoren von farnesylprotein-transferase mit radiosensibilisierenden eigenschaften
ES2237125T3 (es) 1998-08-27 2005-07-16 Pfizer Products Inc. Derivados de quinolin-2-ona utiles como agentes anticancerigenos.
CA2341690C (en) 1998-08-27 2007-04-17 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
US6927024B2 (en) 1998-11-30 2005-08-09 Genentech, Inc. PCR assay
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2001042507A1 (en) 1999-12-09 2001-06-14 Advanced Research & Technology Institute Fluorescent in situ rt-pcr
JP2003523381A (ja) 2000-02-24 2003-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 投与レジメン
CN100523216C (zh) 2001-03-02 2009-08-05 匹兹堡大学 Pcr方法
US7122799B2 (en) 2003-12-18 2006-10-17 Palo Alto Research Center Incorporated LED or laser enabled real-time PCR system and spectrophotometer
US20060078494A1 (en) * 2004-09-24 2006-04-13 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
WO2007110709A2 (en) * 2005-10-14 2007-10-04 Janssen Pharmaceutica, N.V. Formulations of tipifarnib for intravenous administration
WO2010051391A1 (en) * 2008-10-31 2010-05-06 Facet Biotech Corporation Use of anti-cs1 antibodies for treatment of rare lymphomas
US20110281814A1 (en) * 2009-01-30 2011-11-17 Genzyme Corporation Methods and compositions for treating breast cancer
CN103328971B (zh) * 2010-07-28 2016-09-28 维里德克斯有限责任公司 急性髓细胞性白血病应答法尼基转移酶抑制剂治疗的测定方法
EP2476441A1 (de) * 2011-01-13 2012-07-18 Universitat Autònoma De Barcelona Verfahren und Reagenzien zur effizienten und gezielten Abgabe von therapeutischen Molekülen an CXCR4-Zellen
CA2855155A1 (en) * 2011-11-09 2013-05-16 Bristol-Myers Squibb Company Treatment of hematologic malignancies with an anti-cxcr4 antibody
CN103787907B (zh) * 2014-02-17 2015-05-27 华东理工大学 作为法尼基转移酶抑制剂的苯胺类化合物及其用途
WO2017184968A1 (en) * 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors

Also Published As

Publication number Publication date
TW201834652A (zh) 2018-10-01
CN114796218A (zh) 2022-07-29
CN109475550A (zh) 2019-03-15
JP2020508351A (ja) 2020-03-19
JP7289795B2 (ja) 2023-06-12
AU2018225566A1 (en) 2018-11-08
TWI663974B (zh) 2019-07-01
EP3432883A1 (de) 2019-01-30
EP3432883B1 (de) 2021-07-28
TWI738314B (zh) 2021-09-01
IL268722A (en) 2019-10-31
KR102003179B1 (ko) 2019-07-23
AU2018225566B2 (en) 2019-11-07
AU2019203548C1 (en) 2020-01-23
AU2019203548A1 (en) 2019-06-13
AU2019246922A1 (en) 2019-10-31
AU2019203548B2 (en) 2019-08-15
TWI693074B (zh) 2020-05-11
EP3542800B1 (de) 2022-06-01
MX2022008843A (es) 2022-08-10
ES2927228T3 (es) 2022-11-03
BR112019017375A2 (pt) 2020-03-31
WO2018156609A1 (en) 2018-08-30
KR102138904B1 (ko) 2020-07-28
TW202031260A (zh) 2020-09-01
PH12019501918A1 (en) 2020-06-01
MX2019009821A (es) 2019-12-02
EP3542800A1 (de) 2019-09-25
ES2892157T3 (es) 2022-02-02
EP4119142A1 (de) 2023-01-18
CN114712354A (zh) 2022-07-08
CN109999037A (zh) 2019-07-12
TW201929903A (zh) 2019-08-01
KR20190087661A (ko) 2019-07-24
KR20180123723A (ko) 2018-11-19
CA3053795A1 (en) 2018-08-30
KR20200090982A (ko) 2020-07-29

Similar Documents

Publication Publication Date Title
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201901747VA (en) Inhibitors of cellular metabolic processes
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201808990QA (en) Compositions for topical application of compounds
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201807421TA (en) The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
SG11201903786UA (en) Farnesyltransferase inhibitors for use in methods of treating cancer
SG11201804360XA (en) Mat2a inhibitors for treating mtap null cancer
SG11201908743SA (en) Methods and compositions for modulation of immune cells
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201408750VA (en) NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201903076QA (en) Carbamoyl phenylalaninol compounds and uses therof
SG11201908114UA (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
SG11201903312VA (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
SG11201807062RA (en) Anti-tnfalpha-antibodies and functional fragments thereof
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201806622PA (en) Egfl6 specific monoclonal antibodies and methods of their use
SG11201407208UA (en) A method for dynamic generation and modification of an electronic entity architecture